Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: Long-term results

International Journal of Urology

Volumn 5, Issue 1, 1998, Pages 16-21

  Tomita, Yoshihiko ^a   Katagiri, Akiyoshi ^a   Saito, Kazuhide ^a   Imai, Tomoyuki ^a   Saito, Toshihiro ^a   Tanikawa, Toshiki ^a   Terunuma, Masahiro ^b   Nishiyama, Tsutomu ^b   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b Koseiren Nagaoka Chuo General Hospital   (Japan)

Author keywords

Adoptive immunotherapy; Interleukin 2; Lymphokine activated killer cells; Renal cell cancer

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; KIDNEY CANCER; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MALE; PRIORITY JOURNAL;

EID: 0031907142     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1998.tb00227.x     Document Type: Article

References (20)

1. Yagoda A. Chemotherapy of renal cell carcinoma: 1983-1989. Semin Urol 1989;7:199-202.
2. Forman JD. The role of radiation therapy in the management of carcinoma of the kidney. Semin Urol 1989; 7:195-198.
3. Savage PD. Renal cell carcinoma. Current Opin Oncol 1995;7:275-280.
4. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
5. West WH,Tauer KW,Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
6. Fisher RI, Coltman CA Jr., Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, Gemlo BT, Hoth DF, Parkinson DR, Paietta E. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Int Med 1988;108:518-523.
7. Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, Parkinson DR, Wiernik PH, Creekmore SP, Boldt DH. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989;7: 486-498.
8. Hosokawa M, Sawamura Y, Morikage T, Okada F, Xu Z, Morikawa K, Itoh K, Kobayashi H. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. Cancer Immunol Immunother 1988;26:250-256.
9. Tomita Y,Terunuma M, Nishiyama T, Sato S.Treatment of patients with advanced renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide. J Jpn Soc Cancer Ther 1992;27:1789-1795.
10. Thompson JA, Shulrnan KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992; 10:960-968.
11. Koretz MJ, Lawson DH, York RM, Graham SD, Murray DR, Gillespie TM, Levitt D, Sell KM. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 1991;126:898-903.
12. Linehan WM, Walther MM, Alexander RB, Rosenberg SA. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute. Sem Urol 1993;11:41-43.
13. Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Hawkins MJ, Demchak PA, Gucalp R, Fisher RI. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275-281.
14. Fleischmann JD, Kim B. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 1991;145:938-941.
15. Tomita Y, Bilim V, Kawasaki T, Takahashi K, Okan I, Magnusson KP, Wiman KG. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. Int J Cancer 1996;66:322-325.
16. Tomita Y, Kawasaki T, Bilim V, Takeda M, Takahashi K. Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1 (CD95) mediated apoptosis in renal-cell-cancer cells. Int J Cancer 1996;68:132-135.
17. Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T. Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2. Jpn J Urol 1991;82:395-404.
18. Gemlo BT, Palladino MA Jr, Jaffe HS, Espevik TP, Rayner AA. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 1988;48: 5864-5867.
19. Honn KV, Tang DG. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev 1992;11:353-375.
20. Tomita Y, Saito T, Saito K, Oite T, Shimizu F, Sato S. Possible significance ofVLA-4(α4β1) for hematogenous metastasis of renal cell cancer. Int J Cancer 1995;60:753-758.